Taysha Gene Therapies Inc (NASDAQ:TSHA) price on Thursday, February 27, fall -1.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.59.
A look at the stock’s price movement, the close in the last trading session was $1.62. Turning to its 52-week performance, $4.32 and $1.19 were the 52-week high and 52-week low respectively. Overall, TSHA moved 6.00% over the past month.
Taysha Gene Therapies Inc’s market cap currently stands at around $325.86 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 2.48M for the company’s revenue for the quarter, with a low and high estimate of 2M and 3.8M respectively. The average forecast suggests down to a -27.33% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 7.97M, representing a -4.40% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TSHA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 7 recommend TSHA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TSHA’s current price about -2.30% and -6.47% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.07, while 7-day volatility ratio is 9.20% and 9.25% in the 30-day chart. Further, Taysha Gene Therapies Inc (TSHA) has a beta value of 0.88, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $8.5, forecast between a low of $5 and high of $44. Looking at the price targets, the low is -214.47% off current price level while to achieve the yearly target high, price needs to move -2667.3%. Nonetheless, investors will most likely welcome a -434.59% jump to $8.5 which is the analysts’ median price.
If we refocus on Taysha Gene Therapies Inc (NASDAQ:TSHA), historical trading data shows that trading volumes averaged 2.65 million over the past 3 months. The company’s latest data on shares outstanding shows there are 204.94 million shares.
The 23.07% of Taysha Gene Therapies Inc’s shares are in the hands of company insiders while institutional holders own 77.29% of the company’s shares. Current price change has pushed the stock -8.09% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TSHA stock continues to rise going into the next quarter.
